Expand your knowledge.

Advances in NASH Drugs & The Role of NITs

June 10, 2021, 8:30AM PT

Join presenter Dr. Stephen Harrison, a Key Opinion Leader in NASH, to learn about the exciting progress of NASH drugs and non-invasive tests in addressing this emerging health crisis. Key points to be covered:

  • Current management and treatment regimens for NASH
  • Promising therapies on the horizon to manage and treat NASH
  • Advances in non-invasive tests for assisting in the clinical management of patients with liver disease

Featured Speaker(s):

Dr. Stephen Harrison

Dr. Harrison earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology. Dr. Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is internationally known for studies in non-alcoholic fatty liver disease with over 250 peer reviewed publications. Currently, Dr. Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research.

Michael Betel


Mr. Betel is the founder of the Fatty Liver Alliance (fattyliver.ca) and has been a leader in the area of liver disease, in both commercial and not-for-profit organizations for over 25 years, as a Director at Hoffmann-La Roche and Canadian Blood Services, and a sales and marketing leader at Schering-Plough. He was a director on the Board of Directors for the Canadian Liver Foundation for 9 years.  He was the creator of one of the first health related websites in the world, HepNet which highlighted news and current hepatitis related information for physicians, nurses and patients (launched in 1995).

Share With Your Network